Trial | NCT04322344  Report issue

Title

Escin in Patients With Covid-19 Infection
Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    Escin ...

  • Study Participants

    120
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world. There is no specific drug treatment for this disease. Considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in COVID-19 infected patients.
Study Started
Mar 23
2020
Primary Completion
Jun 30
2020
Study Completion
Dec 30
2020
Anticipated
Last Update
Sep 16
2020

Drug Escin

treatment with escin or escinate sodium

Drug standard therapy

antiviral drugs

oral escin group Experimental

Standard therapy+Escin tablet 40mg*3, os for 12 days

control group Sham Comparator

standard therapy

parenteral escin group Experimental

standard treatment + sodium Escinate 20mg iv/day for 12 days

Criteria 

Inclusion Criteria:

Aged between 18 and 75 years, extremes included, male or female
Positivity to covid-19 screening test in molecular biology
In escin group: Low response to standard treatment
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Female subjects who are pregnant or breastfeeding.
patients with previous history to allergy
patients meet the contraindications of escin
Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.
patients can't take drugs orally
No Results Posted